US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.
Multimodal Platform with AI Capabilities
The AVVIGO+ system is a multimodal platform that integrates advanced imaging and functionality. Equipped with artificial intelligence (AI) capabilities, the IVUS system includes the Auxiliary Vascular Assessment (ALA) function, which can automatically execute key steps and deliver intuitive and precise vascular measurement data. This innovation significantly reduces operation time, enhancing the efficiency of medical procedures.
AI-Assisted Vascular Assessment Streamlines PCI Treatment
Furthermore, the system features AI-assisted vascular assessment, empowering physicians to optimize the evaluation process during percutaneous coronary intervention (PCI) treatment. By streamlining the operational workflow, the AVVIGO+ system contributes to shorter procedure times, which is crucial in a clinical setting.
Global Success and Market Expansion
The device has already found success in Europe and the US, where it received clearance for use. The NMPA’s approval in China is expected to further expand the reach of this innovative technology, offering Chinese patients access to a leading-edge diagnostic tool for coronary heart disease.-Fineline Info & Tech
